2 years ago

EyeBiotech Raises $130 Million in Series A Funding

  • EyeBiotech, a London, UK-based clinical-stage ophthalmology biotechnology company, has raised an additional $65 million in Series A funding, bringing the total amount raised to $130 million

  • The round saw participation from new investors Bain Capital Life Sciences, Omega Funds, and Vertex Ventures HC, as well as existing investors SV Health Investors, Jeito Capital, Samsara Biocapital, and MRL Ventures Fund

  • EyeBiotech intends to use the proceeds to accelerate its clinical development program and further build out its innovative retina pipeline

  • The company was founded in August 2021 by David Guyer, M.D., and Tony Adamis, M.D., and is focused on developing new therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.

      • ProblemHealthcare

      "Patients with sight-threatening eye diseases like diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD) suffer from vision loss due to fluid buildup in the retina."

      Solution

      "EyeBio is developing Restoret, a new treatment that acts as an agonist of the Wnt signaling pathway to resolve fluid in the retina and improve visual acuity for patients with NVAMD, DME, and other retinal diseases."

      Covered on